GcMAF - treatment for cancer, aids and immune diseases
It is our immune system that prevents and cures cancer
The first research was published in 1993 and since then many papers have appeared indicating GcMAF cured Cancer and eradicated HIV by simply activating the immune system.
Dr. Nobuto Yamamoto in Philadelphia was the first, but hundreds of scientists have now worked on this and related projects.
How does GcMAF work?
In a healthy person GcMAF instructs macrophages in our bloodstream to scour our bodies and kill malignancies. But malignant cells like cancer send out an enzyme called Nagalase that neutralises the GcMAF; so the macrophages never get the message to go into action – in this way cancer suppresses the immune system, and cancer cells grow unchecked.
To reverse this, we make GcMAF outside the body, and it is injected once a week for 25 weeks for early cancers, 50 or more weeks for late stage cancers. (Encapsulated tumours require additional treatment.) HIV can require as little as 16 weeks.
In its role of immune system regulator, GcMAF reverses other diseases that attack the immune system like Osteoporosis, Aids, Hodgkin’s, Lupus, MS, Fibromyalgia, Parkinson’s, various bacterial and viral infections and various types of Immune dysfunction.
Small pre-clinical trials to build the case are again taking place.
Those diagnosed with any of these illnesses, and who have done their own research on it, are invited to respond. We ask for a copy of diagnostic information and update reports from a physician during and after treatments, to help build the case that GcMAF is a cure for various illnesses, which will help to make it available to the public. Participants are free to stop at any time.
What have we learned?
Dr Yamamoto carefully selected his trials: he took fit people with in the early stages of cancer and HIV, and reported 100% success, with no recurrence after many years. He did not attempt to cure people with large tumours.
Our trials are quite different: most people are over 50, some over 70, with advanced or terminal cancers, with significant tumour mass.
We appear to have had stunning results in 20 percent of cases, and we think we have learned enough to take that figure up to 50% in this 2011 round of trials. GcMAF needs normal levels of vitamin D to function strongly, and those participants see significant tumour shrinkage in 8 weeks. But even in low responders, GcMAF appears to stop the advance of cancer.
We have probably proved GcMAF can work for people up to age 67, with terminal stage 4 cancer, and can completely destroy large tumour mass.
So far those patients who in 8 weeks are cured of symptoms, or whose tumour mass drops significantly, all take exercise, perhaps a 40 minute walk outside each day.
HIV participants should expect to see viral loads drop to zero, and CD4 counts rise by at least 300 points in 16 weeks, and if that doesn't happen we will refund your money.
But the beauty of using your own immune system to cure cancer is that it remembers how to defeat it for the rest of your life: it doesn't come back. And unlike chemotherapy, the side effects are trivial.